Roche: to present new data at hematology congress
(CercleFinance.com) - Roche plans to present data across multiple blood diseases at the upcoming American Society of Hematology (ASH) annual meeting, the Swiss drugmaker said on Thursday.
The company said 10 of its medicines will be featured in over 70 abstracts, including 25 oral presentations, across 15 blood diseases, over the course of the medical congress.
Amongst them, Roche's new hemophilia drug Hemlibra will be featured in 12 abstracts, it said.
Roche will also share data for medicines for a range of blood cancers and will unveil early data for two novel T-cell engaging bispecific antibodies in non-Hodgkin lymphoma.
The American Society of Hematology (ASH) annual meeting will take place from 1 to 4 December in San Diego.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The company said 10 of its medicines will be featured in over 70 abstracts, including 25 oral presentations, across 15 blood diseases, over the course of the medical congress.
Amongst them, Roche's new hemophilia drug Hemlibra will be featured in 12 abstracts, it said.
Roche will also share data for medicines for a range of blood cancers and will unveil early data for two novel T-cell engaging bispecific antibodies in non-Hodgkin lymphoma.
The American Society of Hematology (ASH) annual meeting will take place from 1 to 4 December in San Diego.
Copyright (c) 2018 CercleFinance.com. All rights reserved.